In brief: CSL, Progen Industries, Mayne Group
Tuesday, 28 June, 2005
CSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12. "Combined with the buyback completed in May of this year it is likely that we will have returned to shareholders in excess of the AUD$550 million we raised to acquire the global plasma therapeutics business of Aventis Behring in December 2004. At the same time the market value for CSL has more than doubled since making the announcement to acquire the business," said CSL managing director Brian McNamee in a statement.
Progen Industries (ASX:PGL; NASDAQ:PGLAF) has engaged San Francisco-based global life sciences merchant bank Burrill & Company to accelerate a partnering transaction for the company's lead anti-cancer product PI-88. Progen's vice president business development Darren Schliebs has resigned.
Mayne Group (ASX:MAY) has appointed Nora Scheinkestel as a non-executive director effective July 1.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
